Brazil's weight‑loss injection pens reshape food market and health research

In Brazil, the growing use of injectable GLP‑1 agonist drugs such as semaglutide and tirzepatide—often called “weight‑loss pens”—is altering consumer eating habits. A recent survey found that one‑third of Brazilian households have at least one person who has used these medicines, leading to reduced consumption of sweets, snacks, sugary drinks, pasta and other high‑carbohydrate foods, while demand for lean protein, fruit, vegetables and whole‑grain products rises. Food retailers and restaurants in states such as Goiás are adjusting menus and product lines to meet the new preference for smaller, more nutritious portions.

The obesity‑drug market in Brazil generates about R$ 10 billion annually and is expected to expand further as generic versions lower prices. Researchers are also investigating whether GLP‑1 agonists may lower the risk of cancers linked to obesity. Observational data presented at the 2025 ASCO meeting, covering more than 170,000 adults with obesity and diabetes, showed a reduced incidence of several obesity‑related cancers among users of these drugs compared with non‑users. While the findings suggest a possible protective effect, experts note that causal evidence is still lacking and that long‑term clinical trials are needed.